A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies
Public ClinicalTrials.gov record NCT05336409. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The ELiPSE-1 Study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects With Relapsed or Refractory CD19-Positive B-Cell Malignancies
Study identification
- NCT ID
- NCT05336409
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Century Therapeutics, Inc.
- Industry
- Enrollment
- 28 participants
Conditions and interventions
Conditions
Interventions
- CNTY-101 Biological
- IL-2 Biological
- Lymphodepleting Chemotherapy Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 23, 2023
- Primary completion
- Jun 30, 2025
- Completion
- Jun 30, 2025
- Last update posted
- Dec 17, 2025
2023 – 2025
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| University of Southern California - Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| University of California San Diego, Moores Cancer Center | San Diego | California | 92093 | — |
| Medstar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| University of Kentucky - Markey Cancer Center | Lexington | Kentucky | 40536 | — |
| University of Maryland Medical Center | Baltimore | Maryland | 21201 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Corewell Health | Grand Rapids | Michigan | 49503 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45229 | — |
| Oncology Hematology Care, Inc-Kenwood | Cincinnati | Ohio | 45236 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| UT Southwestern | Dallas | Texas | 75390 | — |
| Houston Methodist Research Institute | Houston | Texas | 77030 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05336409, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 17, 2025 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05336409 live on ClinicalTrials.gov.